Congenital Hyperinsulinism - Pipeline Insight, 2026

DelveInsight's, "Congenital Hyperinsulinism - Pipeline Insight, 2026" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Congenital Hyperinsulinism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Congenital Hyperinsulinism: Understanding

Congenital Hyperinsulinism: Overview

Congenital hyperinsulinism is a rare genetic disorder characterized by inappropriate and excessive secretion of insulin from pancreatic B-cells, resulting in recurrent episodes of hypoglycemia (low blood glucose), particularly in neonates and infants. Insulin normally regulates blood glucose levels, but in this condition, insulin secretion occurs even when glucose levels are low, leading to persistent hypoglycemia that can cause severe neurological complications such as seizures, brain damage, or coma if untreated. The condition shows wide clinical variability, ranging from mild to severe forms, and may present shortly after birth or during early childhood.

The primary cause of congenital hyperinsulinism is genetic mutations affecting the regulation of insulin secretion in pancreatic B-cells. Mutations in genes such as ABCC8 and KCNJ11, which encode components of ATP-sensitive potassium (K_ATP) channels, are the most common causes. These mutations disrupt normal insulin regulation, leading to continuous insulin release regardless of blood glucose levels. In transient cases, non-genetic factors such as maternal diabetes, intrauterine growth restriction, or perinatal stress may contribute. In some patients, the exact cause remains unidentified.

The pathophysiology of congenital hyperinsulinism involves dysregulation of insulin secretion from pancreatic B-cells due to defective glucose-sensing and ion channel mechanisms. Normally, insulin secretion is tightly regulated by blood glucose levels through ATP-sensitive potassium channels. In this condition, mutations impair these channels, causing persistent depolarization of B-cells and continuous insulin release. Excess insulin promotes glucose uptake into tissues, inhibits gluconeogenesis and glycogenolysis, and suppresses ketone production, resulting in severe hypoglycemia and lack of alternative energy sources for the brain. This leads to neuroglycopenia and potential neurological damage.

Diagnosis of congenital hyperinsulinism is based on biochemical and clinical findings during episodes of hypoglycemia. Key diagnostic features include inappropriately detectable or elevated insulin levels during hypoglycemia, low ketone bodies and free fatty acids, and a rise in blood glucose following glucagon administration. Additional investigations include genetic testing to identify causative mutations and imaging techniques such as PET scans to differentiate focal from diffuse disease. Early diagnosis is critical to prevent irreversible neurological damage.

The primary goal of treatment is to maintain normal blood glucose levels and prevent neurological complications. Initial management includes frequent feeding or intravenous glucose infusion. Pharmacological therapy commonly involves drugs such as diazoxide, which inhibits insulin secretion, and somatostatin analogs in resistant cases. In severe or drug-unresponsive cases, especially focal disease, surgical intervention such as partial pancreatectomy may be required. Long-term management depends on the underlying genetic cause and disease severity.

"Congenital Hyperinsulinism- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Hyperinsulinism pipeline landscape is provided which includes the disease overview and Congenital Hyperinsulinism treatment guidelines. The assessment part of the report embraces, in depth Congenital Hyperinsulinism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Hyperinsulinism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Congenital Hyperinsulinism R&D. The therapies under development are focused on novel approaches to treat/improve Congenital Hyperinsulinism.

Congenital Hyperinsulinism Emerging Drugs Chapters

This segment of the Congenital Hyperinsulinism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Congenital Hyperinsulinism Emerging Drugs

• Ersodetug: Rezolute

Ersodetug (RZ358), developed by Rezolute, is an investigational fully human monoclonal antibody designed to treat hypoglycemia caused by hyperinsulinism, including Congenital Hyperinsulinism. The drug works through a novel mechanism of action by binding to the insulin receptor and reducing excessive insulin signaling, thereby counteracting the effects of abnormally high insulin levels rather than suppressing insulin secretion itself. It is being developed primarily for hypoglycemia due to congenital hyperinsulinism and other forms of hyperinsulinism, addressing a significant unmet medical need in rare diseases. Ersodetug has received multiple regulatory designations, including FDA Breakthrough Therapy Designation for congenital hyperinsulinism, as well as additional designations such as PRIME (EMA) and ILAP Innovation Passport (UK), reflecting its potential clinical benefit. The drug has advanced into Phase III clinical trials (sunRIZE study) for congenital hyperinsulinism.

Congenital Hyperinsulinism: Therapeutic Assessment

This segment of the report provides insights about the different Congenital Hyperinsulinism drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Congenital Hyperinsulinism

There are approx. 4+ key companies which are developing the therapies Congenital Hyperinsulinism. The companies which have their Congenital Hyperinsulinism drug candidates in the most advanced stage, i.e. Phase III include, Rezolute, and others.

• Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Congenital Hyperinsulinism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Congenital Hyperinsulinism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Congenital Hyperinsulinism drugs.

Congenital Hyperinsulinism Report Insights

• Congenital Hyperinsulinism Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Congenital Hyperinsulinism Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Congenital Hyperinsulinism drugs?
• How many Congenital Hyperinsulinism drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Congenital Hyperinsulinism?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Congenital Hyperinsulinism therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Congenital Hyperinsulinism and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Rezolute
• Hanmi Pharmaceutical

Key Products

• Ersodetug
• Efpegerglucagon